Bluebird bio — Investor Presentation (July 2023)
27 slides from Bluebird bio's investor presentation, Jul 12, 2023
Slide 1: bluebird bio Company Presentation July 2023
bluebird bio Company Presentation July 2023 NASDAQ: BLUE Exhibit 99.1
Slide 2: Forward-looking statements
These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre
Slide 3: To give patients and their families more bluebird days
TO GIVE PATIENTS AND THEIR FAMILIES MORE BLUEBIRD DAYS
Slide 4: Demonstrating gene therapy expertise
~22,000 patients potentially addressable with our 3 programs in the U.S.1 Demonstrating gene therapy expertise 1 Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512 521; Jul ’21 bbb analysis of Komodo patient-level claims data (Apr ’20 – Mar ’21),
Slide 5: Three established gene therapy programs
Three established gene therapy programs 63 patients treated across all clinical trials 8 years of follow-up (n = 3) In Phase 3 studies (n=41), 90% of patients achieved transfusion independence Safety profile generally consistent with that seen with cell collection and myeloablative conditioning 50 p
Slide 6: Momentum building with near-term commercial launches
Momentum building with near-term commercial launches; opportunity to deliver significant value for patients and shareholders 1,300-1,500 Patients potentially eligible for ZYNTEGLO® for beta-thalassemia ~20,000 40 Patients potentially eligible for SKYSONA® for Cerebral adrenoleukodystrophy FUTURE GRO
Slide 7: Inherited hemoglobin disorders
Inherited hemoglobin disorders
Slide 8: Launching now: ZYNTEGLO
Launching now zynteglo (betibeglogene autotemcel) suspension for IV infusion
Slide 9: ZYNTEGLO commercial launch off to a strong start
ZYNTEGLO commercial launch off to a strong start Access & Reimbursement Patient Interest QTC Network Launch built on three key pillars ZYNTEGLO ®
Slide 10: Qualified Treatment Center network being activated in waves
Fit-for-purpose Qualified Treatment Center (QTC) network being activated in waves QTC: Qualified Treatment Center Anticipated expansion to ~40-50 QTCs by YE 2023 to maximize opportunity for ZYNTEGLO and in anticipation of lovo-cel launch QTC growth aligned with demand Targeted QTC selection Focused
Slide 11: Timely access and reimbursement with upfront payment at $2.8M price
Confident in timely, quality access and reimbursement with upfront payment at $2.8M price SIMPLE AND INNOVATIVE PAYMENT STRATEGY ENCOURAGING PAYER INTERACTIONS 1 Date on file 2 Weiss et al. 2019 3 TIF Guidelines PRICE TIED TO RECOGNIZED VALUE Beta-thalassemia requiring regular RBC transfusions is as
Slide 12: Early indications show value of ZYNTEGLO is recognized
Early indications show value of ZYNTEGLO is recognized SIMPLE AND INNOVATIVE PAYMENT STRATEGY ENCOURAGING PAYER INTERACTIONS PRICE TIED TO RECOGNIZED VALUE Beta-thalassemia requiring regular RBC transfusions is associated with: $6.4 million average lifetime medical care cost per patient1 23X higher
Slide 13: ZYNTEGLO manufacturing allows flexible scheduling
ZYNTEGLO® manufacturing allows for flexible scheduling and is designed to deliver high quality drug product Apheresis and Cell Collection Drug Product Manufacturing and Testing Drug Product Ready to Ship Infusion and Recovery 70-90 Days Occurs at QTC Occurs at CMO Bulk of time spent on release testi
Slide 14: ZYNTEGLO enables seamless transition to lovo-cel
ZYNTEGLO expected to enable seamless transition to commercializing lovo-cel for sickle cell disease ZYNTEGLO ® Access & Reimbursement Patient Interest QTC Network Established confidence with payers Same treating physicians Same QTC network LOVO-CEL
Slide 15: Large patient population, significant unmet need in sickle cell disease
LARGE PATIENT POPULATION SIGNIFICANT UNMET NEED MEANINGFUL OPPORTUNITY 1 CDC 2 Data on file3 Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005 3 Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. 4 Holdford et al 2021 5 Gallagher ME et
Slide 16: lovo-cel PDUFA goal date of December 20, 2023
lovo-cel PDUFA goal date of December 20, 2023 BLA includes: HGB-206 Group C as primary basis of effectiveness 36 patients with a median 32 months of follow-up and 2 patients in the HGB-210 study with 18 months of follow-up Pivotal study HGB-206; largest gene therapy study in SCD to date with clinica
Slide 17: Planned 2023 network expansion for lovo-cel launch
Planned 2023 network expansion ensures QTCs are in place and ready to treat appropriate SCD patients upon FDA approval of lovo-cel *Graphic is illustrative and subject to change as final QTC network is determined; Activated QTC defined as Qualified Treatment Center with a signed MSA; Activated QTCs
Slide 18: SKYSONA
Z ‘ = PS i SKYSONA®
Slide 19: SKYSONA launching now
Launching now First commercial infusion has been completed; in total cell collection completed for three patients for SKYSONA Three activated QTCs Zero ultimate denials to date; payers recognize value and urgency to treat Anticipate 5-10 patient starts in 2023 Early, active cerebral adrenoleukodystr
Slide 20: Closing
Closing 4 :
Slide 21: Strong financial position – cash burn and runway horizon
Strong financial position – cash burn and runway horizon CASH & CASH EQUIVALENTS Current cash runway into Q4 20242 Continuing to strengthen balance sheet beyond Q4 2024 1. Cash balance contains $45m in restricted cash.; 2. Without the release of our restricted cash, we estimate our cash, cash equiva
Slide 22: Setting the standard and proving the gene therapy commercial model
bluebird bio: Setting the standard and proving the gene therapy commercial model Demonstrating gene therapy expertise across clinical, regulatory and commercial Momentum building with near-term commercial launches Opportunity to deliver significant value for patients and shareholders
Slide 23: Upcoming milestones
First to market gene therapy for inherited hemoglobin disorders in the U.S. Proving our commercial model Significant value driver PDUFA date December 20, 2023 Commercial launch expected early 2024 First commercial revenue expected in Q2 2023 Continued launch expansion throughout 2023 40-50 QTCs by e
Slide 24: Thank you
Slide 25: ZYNTEGLO approval underscored by clinical study data
ZYNTEGLO® approval is underscored by impressive clinical study data **After a planned orthopedic surgery, the patient had blood loss, which required 1 packed red blood cell transfusion Data as of July 2022 90% of patients achieved transfusion independence (TI) and normal or near-normal hemoglobin le
Slide 26: lovo-cel: most advanced sickle cell disease gene therapy program
lovo-cel: most advanced sickle cell disease gene therapy development program in the industry Update on Pivotal Cohort (HGB 206 Group C) Presented at ASH 2022 96% experienced complete resolution of severe VOEs through 24 months of follow-up (ASH 2022) As of August 2022, 50 patients had been treated w
Slide 27: SKYSONA FDA approval based on post hoc enrichment analysis
FDA approval was based on a post hoc enrichment analysis of 24-month improvement in major functional disability (MFD) free survival SKYSONA treated patients (n = 11) had an estimated 72% likelihood of MFD-free survival at 24 months compared to untreated patients in a natural history study (n = 7) wh